The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018.
BioCentury’s analysis of abstracts released ahead of this year’s meeting of the American Society of Hematology (ASH) identifies 19 new and 58 emerging targets (see “Table: New Targets at ASH 2018” and “Figure: Emerging Functions”).
BioCentury identified 58 emerging targets in abstracts at the 2018 meeting of the American Society of Hematology (ASH) 2018 meeting, where “emerging” is defined as a target whose mentions increased at least threefold over last year. Specifically, at ASH 2017, each emerging target was featured in zero, one or two abstracts, whereas in 2018, each target was featured in four or more. Of these, 52 clustered into eight functional categories with at least three members each. The adhesion category includes mechanosensors and extracellular matrix regulators; it also includes one target family, lectins, which appeared in seven abstracts this year vs. two in 2017. The other emerging target classes consist of gene expression regulators such as epigenetic modifiers, transcription factors and RNA-binding proteins; innate immune regulators of phagocytosis, antigen presentation and NK cell activity; post-translational modifiers such as kinases, phosphatases, sugar-modifying enzymes, ubiquitin-like molecules and endoplasmic reticulum-targeting proteins; and targets involved in growth factor and hormone signaling, metabolism, oxidative damage and hypoxia, and apoptosis. Full target names can be found in BioCentury’s BCIQ database. Source: ASH 2018 abstracts as of Nov. 1
Select new cancer targets presented at the 2018 American Society of Hematology (ASH) meeting. The list includes proteins with proposed therapeutic or biomarker potential based on